The effects of pituitary adenylate cyclase-activating polypeptide on acute and chronic morphine actions in mice

Mónika Mácsai, Imre Pataki, Gábor Tóth, Gyula Szabó

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on pain sensitivity, on morphine analgesia, on morphine tolerance and withdrawal were investigated in mice. The heat-radiant tail-flick test was used to assess antinociceptive threshold. Intracerebroventricular (i.c.v.) administration of PACAP alone had no effect on pain sensitivity but in a dose of 500 ng, it significantly diminished the analgesic effect of a single dose of morphine (2.25 mg/kg, s.c.). PACAP (500 ng, i.c.v.) significantly increased the chronic tolerance to morphine and enhanced the naloxone (1 mg/kg, s.c.)-precipitated withdrawal jumping. Theophylline (1 mg/kg, i.p.) pretreatment significantly enhanced the effect of PACAP on morphine analgesia but the effects of PACAP on tolerance and withdrawal were unaffected upon theophylline administration. On the grounds of our previous studies with vasoactive intestinal polypeptide (VIP), it appears that different receptors are involved in the effects of PACAP in acute and chronic morphine actions. Our results indicate that PACAP-induced actions likely participate in acute and chronic effects of morphine and suggest a potential role of PACAP in opioid analgesia, tolerance and withdrawal.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalRegulatory Peptides
Volume109
Issue number1-3
DOIs
Publication statusPublished - Nov 15 2002

    Fingerprint

Keywords

  • Analgesia
  • Morphine
  • Mouse
  • PACAP
  • Tolerance
  • Withdrawal

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Endocrinology
  • Clinical Biochemistry
  • Cellular and Molecular Neuroscience

Cite this